http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005116033-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93e457a1b17d6aa34429a9de91b9c212 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01f4dfbf7e928b2477534a09534993e7 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-12 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
filingDate | 2005-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41c59bf25e4ef7f1538340038c028402 |
publicationDate | 2005-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-2005116033-A1 |
titleOfInvention | Immuno inhibitory heterocyclic compounds |
abstract | Compounds of formula (I) are CD80 inhibitors, and of value for immunomodulation, e.g. in rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis: wherein Y is-CH2-,-CH2CH2-, or CH2CH2CH2-; R1 represents H; F; methyl, trifuoromethyl, methoxy or triflioromethoxy; R3 represents H; F; CI; Br; NO2; CN; C1C6 alkyl optionally substituted by F or Cl; or C1-C6 alkoxy optionally substituted by F; R4 represents a carboxylic acid group (-COOH) or an ester thereof, or-C(=O) NR6R7-NR7C(=O)R6, NR7C(=O)OR6, NHC(=O) or NHC(=S)NR7R6 wherein R6 and R7 are as defined in the specification and X represents a bond or a divalent radical as defined in the specification. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8309552-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7932253-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2883883-A1 |
priorityDate | 2004-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 177.